Home News Insights Trading halts Paper trading Guide Community My account

Market calendarChecking market schedule

Display in USD

Loading news article.

About WAPE
U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Immuneering Announces Acceptance of Two Abstracts for 2026 EORTC-NCI-AACR Symposium | WAPE

Back All news

Newsfiscal.ai

Immuneering Announces Acceptance of Two Abstracts for 2026 EORTC-NCI-AACR Symposium

Nov 4, 2026, 09:03 ET · Published

View source

Article summary

Immuneering Corporation announced that two abstracts evaluating its lead investigational candidate, atebimetinib (IMM-1-104), have been accepted for presentation at the upcoming 2026 EORTC-NCI-AACR Symposium.

An excerpt from the original article.

Related companies

Immuneering Corporation Class A Common StockIMRXView stock

Immuneering Announces Acceptance of Two Abstracts for 2026 EORTC-NCI-AACR Symposium

Article summary

Related companies

Analyzed by WAPE AI.

Comments —